This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Galantamine (reminyl) in the treatment of severe Alzheimer’s disease


Gavrilova, S. I., Kolykhanov, I. V., Kalyn, Ia B., Selezneva, N. D.


Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 109, No.: 7, Pages.: 57-61

Year of Publication



Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the antipsychotic therapy. Reminyl had a positive effect on cognitive functions and psychotic symptoms of dementia, in particular delusions, aggression and irritability, apathy, aberrant motor behavior, eating and sleep disorders. The therapeutic reduction of these disorders resulted in the distinct reduction of physical and mental burden on the caregivers. The therapeutic effects of reminyl and its good tolerability allow to recommend this drug for treatment of severe stages of AD.;


administration & dosage, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, cognition, diagnosis, drug effects, drug therapy, female, galantamine, humans, male, middle aged, reminyl, severity of illness index, therapeutic use, treatment outcome

Types of Dementia

Alzheimer’s Disease

Types of Study

Case Control Study

Type of Outcomes

Behaviour, Carers’ Mental Health, Carers’ Physical Health, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime, Antipsychotics and antidepressants